IGC Pharma Files 2025 Annual Meeting Proxy Materials

TL;DR

IGC Pharma's proxy materials are in for the 2025 annual meeting. Vote your shares!

AI Summary

IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) is filing a Definitive Additional Materials proxy statement for its 2025 Annual Meeting. The company, incorporated in Maryland with its fiscal year ending March 31, is in the Pharmaceutical Preparations industry. The filing is related to the proxy statement for the annual meeting.

Why It Matters

This filing provides shareholders with essential information and voting materials for the company's annual meeting, allowing them to participate in corporate governance decisions.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual meeting, not indicating any immediate financial distress or significant corporate action.

Key Players & Entities

• IGC Pharma, Inc. (company) — Registrant
• India Globalization Capital, Inc. (company) — Former company name
• 2025 (date) — Annual Meeting Year

FAQ

Filing Documents

• igcdefa14a081825.htm (DEFA14A) — 34KB
• image_001.jpg (GRAPHIC) — 6KB
• image_002.jpg (GRAPHIC) — 49KB
• image_003.jpg (GRAPHIC) — 10KB
• image_004.jpg (GRAPHIC) — 2KB
• 0001185185-25-001023.txt ( ) — 128KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 IGC Pharma, Inc. (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Your Vote Counts! IGC PHARMA, INC. 2025 Annual Meeting Vote by October 09, 2025 11:59 PM ET You invested in IGC PHARMA, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on October 10, 2025. Get informed before you vote View the Notice & Proxy Statement, Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to September 28, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote in Person at the Meeting* October 10, 2025 11:00 AM EST 10224 Falls Road Potomac, Maryland, 20854 * If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. IGC PHARMA, INC. 2025 Annual Meeting Vote by October 09, 2025 11:59 PM ET Voting Items Board Recommends 1. Election of Directors For Nominees: 1A MR. RAM MUKUNDA 1B MR. JAMES MORAN For 2 To ratify the appointment of Manohar Chowdhry & Associates, as the Company’s independent registered public accounting firm for the 2026 fiscal year For 3 To approve the grant of 5,000,000 shares of common stock, governed by the Company’s 2018 Omnibus Incentive Plan, to be granted from time to time to the Company’s current and new employees, advisors, directors, and consultants by the Board of Directors, pursuant to certain metrics including performance, vesting, and incentive as set by the Board of Directors and or the CEO For 4 To effect an amendment to our Amended and Restated Articles of Incorporation to increase the authorized number of shares of our common stock from 150,000,000 shares to 600,000,000 shares of common stock For 5 To act upon such other matters as may properly come before the Annual Meeting, including any proposal to adjourn or postpone of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies (the Adjournment Proposal) Such other business as may properly come before the meeting or any adjournment thereof For

View Full Filing

View this DEFA14A filing on SEC EDGAR